• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Philips leads consortium todevelop novel drug therapy

Diagnostic ImagingDiagnostic Imaging Vol 31 No 4
Volume 31
Issue 4

A consortium of more than a dozen European companies and universities is exploring the use of ultrasound and MR to guide or even unleash therapeutic drugs.

A consortium of more than a dozen European companies and universities is exploring the use of ultrasound and MR to guide or even unleash therapeutic drugs. The drugs will float through the bloodstream inside gas-filled bubbles no bigger than red corpuscles. The gas contents naturally lend themselves to tracking by ultrasound. Alternatively, membranes surrounding the gas might be labeled with magnetic particles to allow surveillance by MR. Highenergy ultrasonic pulses or increased temperatures from radio waves burst the bubbles as they arrive at the tumor, releasing the drugs inside.

Philips is leading the four-year program, dubbed SonoDrugs, which has a budget of nearly €16 million ($20.5 million). Its goal is to develop precisely targeted drug delivery systems for treating cancer or cardiovascular diseases, according to the Dutch company.

Just as MR or ultrasound will track the microbubbles as they enter the disease site, so will these modalities be used to monitor the release of the drugs being carried. Precise targeting of the drugs may increase therapeutic efficiency and minimize side effects, according to Henk van Houten, senior vice president of Philips Research and head of Philips’ healthcare research program. It may also provide a way to tailor therapy to individual patients.

The SonoDrugs consortium consists of Philips, Nanobiotix, and Lipoid AG; university medical centers Erasmus Medical Center (the Netherlands) and Universitäts Klinikum Münster (Germany); and academic institutions University of Cyprus (Cyprus), University of Ghent (Belgium), University of Helsinki (Finland), University of London (U.K.), University of Tours (France), University Victor Segalen Bordeaux (France), University of Technology Eindhoven (the Netherlands), and University of Udine (Italy).

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.